INO241122P3500
- 0.00
- 0.000.00%
Inovio Pharmaceuticals Newsroom
Oppenheimer Maintains Inovio Pharmaceuticals(INO.US) With Buy Rating, Cuts Target Price to $15
The Analyst Landscape: 4 Takes On Inovio Pharmaceuticals
Inovio Pharma Price Target Cut to $5.00/Share From $12.00 by HC Wainwright & Co.
Oppenheimer Maintains Outperform on Inovio Pharmaceuticals, Lowers Price Target to $15
Cautious Hold Recommendation on Inovio Pharmaceuticals Amid Financial Challenges and Competitive Pressures
JMP Securities Maintains Inovio Pharmaceuticals(INO.US) With Buy Rating, Maintains Target Price $18
Inovio Pharmaceuticals: Strategic Progress and Promising Pipeline Justify Buy Rating
The "Diet Duo" leads a sharp decline in pharmaceutical stocks, as Trump's new health secretary opposes vaccines and weight loss drugs.
Kennedy, known as the "anti-vaccine pioneer," strongly opposes GLP-1 drugs, believing they are the wrong approach to addressing the obesity crisis. On Friday, the stock prices of the "weight loss giants" eli lilly and co and novo-nordisk a/s fell by 4.93% and 3.4%, respectively, and other companies dedicated to developing weight loss drugs also suffered heavy losses.
Inovio Pharmaceuticals Third Quarter 2024 Earnings: US$0.89 Loss per Share (Vs US$1.52 Loss in 3Q 2023)
Sell-off of US vaccine stocks intensifies! Analyst: Little Kennedy brings uncertainty to the entire industry.
1. On Friday Eastern Time, vaccine manufacturers' stocks plummeted as Donald Trump selected vaccine skeptic Kennedy as Health Secretary, causing industry uncertainty. Moderna, Novavax, Pfizer, and other stock prices were all affected. 2. Analysts pointed out that Kennedy's anti-vaccine stance may weaken public trust in vaccines, leading to a decrease in the vaccination rate in the USA, increasing the risk of outbreaks of diseases such as measles and whooping cough.
Inovio Pharma Is Maintained at Sector Perform by RBC Capital
Inovio Pharmaceuticals Analyst Ratings
RBC Capital Maintains Inovio Pharmaceuticals(INO.US) With Hold Rating, Cuts Target Price to $6
RBC Capital Sticks to Its Hold Rating for Inovio Pharmaceuticals (INO)
Express News | Inovio Pharmaceuticals Inc : RBC Cuts Target Price to $6 From $7
Inovio Pharmaceuticals Advances DNA Medicine Development
Vaccines stocks in the usa collectively plummet! Trump surprisingly appoints an anti-vaccine advocate as the Secretary of Health in the usa.
① Trump nominated Robert F. Kennedy Jr. as the new Secretary of Health and Human Services, which triggered a sell-off in vaccine companies; ② Kennedy advocates very radical views, opposing vaccines since 2005, and questioning the transparency of the usa government in public health information.
Inovio Pharmaceuticals, Inc. (INO) Q3 2024 Earnings Call Transcript Summary
Express News | Inovio Pharmaceuticals Inc: Estimates Its Cash Runway to Extend Into Q3 of 2025
Inovio Pharmaceuticals | 10-Q: Q3 2024 Earnings Report